Journal
MEDICAL ONCOLOGY
Volume 27, Issue -, Pages 1-6Publisher
HUMANA PRESS INC
DOI: 10.1007/s12032-010-9442-2
Keywords
Multiple myeloma; Stem cell transplantation; Lenalidomide; Thalidomide; Bortezomib
Categories
Ask authors/readers for more resources
Multiple myeloma is a clonal B-cell malignancy characterized by aberrant expression of plasma cells wtihin the bone marrow, and is associated with the well known clinical manifestations anemia, bone disease, renal dysfunction, hypercalcemia, and recurrent infections. For many years, melphalan and prednisone represented the standard of care in multiple myeloma therapy, with stem cell transplantation reserved for selected patients. Treatment of the disease has evolved rapidly over the past decade, however, with the development and utilization of thalidomide, lenalidomide, and bortezomib. As a result of these developments, clinical outcomes have improved significantly. This review highlights important historic landmarks as well as more recent events that have played an important role in the evolution of myeloma therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available